Hints and tips:
Related Special Reports
Related Topics
...Moderna’s Covid-19 vaccine was approved for use in the UK in January 2021....
...Moderna generated sales of $18.4bn in 2022 from its Spikevax vaccine....
...Moderna’s decision comes as the company aims to convince investors it can expand its product pipeline....
...Moderna swung to a loss in 2023 as the Covid-19 vaccine maker suffered a sharp reversal in fortunes due to lower uptake of its jab....
...Moderna’s shares surged 15.5 per cent after investment bank Oppenheimer upgraded its stock in anticipation of new product launches in the next 12 to 18 months....
...New data from Moderna and Merck this week offered a promising update on this front....
...Moderna missed earnings expectations in the third quarter after booking $3.1bn in charges related to scaling back vaccine manufacturing operations and deferred tax allowances....
...This helped Moderna beat sales expectations in the third quarter....
...Moderna paid $1,053,767 for security services to Stéphane Bancel, after not disclosing any security payments for him the previous year....
...In the letter, Shah complained about how competitor Moderna’s market value was 10 times 2024 sales, while Novavax’s market capitalisation was below its 2024 sales....
...While Moderna and AstraZeneca specialise in mRNA and viral vector vaccines respectively, there are other vaccine types that were once thought worth pursuing but since dropped....
...Moderna’s latest Covid-19 vaccine can tackle the potentially dangerous new variant BA.2.86, according to a lab test conducted by the company....
...Moderna is discussing the approval process with regulators....
...Moderna needs to show more proof that it is not a one trick pony....
...Moderna shares were up 8.6 per cent in Wall Street trading on Monday morning....
...Moderna declined to comment on pricing levels....
...Stephen Hoge, Moderna’s president, told the Financial Times that in the past year, Moderna had quickly learned how to improve the shot....
...The S&P 500 added 0.1 per cent on Tuesday, with biotech group Moderna the best performing stock, up 6.2 per cent. Real estate and utilities were the best performing sectors on the day....
...Moderna: The pharmaceutical group will hold its annual investor day, when shareholders will be keen to learn more about how it plans to grow its business beyond the Covid-19 pandemic....
...Moderna raised its sales forecast for its Covid-19 jab on Thursday as it prepares for the introduction of private market sales in the US....
...The US federal drug regulator has approved new Covid-19 boosters from Moderna and Pfizer, as it moves to contain infections from spreading more quickly in the US....
...Stock moves to watch on the New York Stock Exchange include Apple, Moderna, and Avangrid....
...Moderna declined to comment on reports in Chinese media that the deal was worth $1bn....
...Earnings: Keurig Dr Pepper, Moderna and mining group Teck will release earnings before the bell. Booking Holdings, Block, and Intuit will report earnings after the market closes....
International Edition